Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review.

Simple Summary: The combination of docetaxel and ramucirumab is a standard second-line treatment for patients with advanced metastatic non-small-cell lung cancer (NSCLC); however, evidence supporting this regimen comes from the REVEL trial conducted before the introduction of immune checkpoint inhib...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 32; no. 11; pp. 612 - 628
Main Authors:	Loizidis, Sotiris, Vogazianos, Paris, Kordatou, Zoe, Fotopoulos, Georgios, Orphanos, George, Kyriakou, Flora, Charalambous, Haris
Format:	Journal Article
Published:	MDPI Nov2025
Online Access:	View this record in EBSCOhost